<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:673f8823-328c-4eb0-b8f2-ed05fe5d2f31,g:8d8adeba-398b-4daa-aa78-acc99a0f42d7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="flks-20230630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_15cde0f9-00d0-41d6-92c6-3945b0f652e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_AccruedExpensesAndOtherCurrentLiabilities_a11b2ae0-54d3-4f06-90ef-dccddc67019e" xlink:href="flks-20230630.xsd#flks_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_15cde0f9-00d0-41d6-92c6-3945b0f652e1" xlink:to="loc_flks_AccruedExpensesAndOtherCurrentLiabilities_a11b2ae0-54d3-4f06-90ef-dccddc67019e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_50daa292-ff46-428c-8415-02fe46157968" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_15cde0f9-00d0-41d6-92c6-3945b0f652e1" xlink:to="loc_us-gaap_AccountsPayableCurrent_50daa292-ff46-428c-8415-02fe46157968" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fea754b2-26ca-48ed-abc0-23a13f616c39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_2c19a17e-25bc-45b7-baa5-23b5885234e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fea754b2-26ca-48ed-abc0-23a13f616c39" xlink:to="loc_us-gaap_PreferredStockValue_2c19a17e-25bc-45b7-baa5-23b5885234e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_6ac4147f-3c2d-4453-aa10-b1b874548a50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fea754b2-26ca-48ed-abc0-23a13f616c39" xlink:to="loc_us-gaap_CommonStockValue_6ac4147f-3c2d-4453-aa10-b1b874548a50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_53545759-3219-4476-8c76-172cd0756198" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fea754b2-26ca-48ed-abc0-23a13f616c39" xlink:to="loc_us-gaap_AdditionalPaidInCapital_53545759-3219-4476-8c76-172cd0756198" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2dc2dd9c-5666-46ed-b19a-f04428074c01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fea754b2-26ca-48ed-abc0-23a13f616c39" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2dc2dd9c-5666-46ed-b19a-f04428074c01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_a77a4df8-1287-4e4f-90df-4292ec4b4ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_145627d4-a003-4ecd-8f0b-75bc78c59fea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a77a4df8-1287-4e4f-90df-4292ec4b4ab7" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_145627d4-a003-4ecd-8f0b-75bc78c59fea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c02ef2e5-7bfc-453c-ba56-416c10b49ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a77a4df8-1287-4e4f-90df-4292ec4b4ab7" xlink:to="loc_us-gaap_AssetsCurrent_c02ef2e5-7bfc-453c-ba56-416c10b49ce3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_aa3d3ca0-a524-4490-b1d0-8dca81cde314" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3d33f2bb-b2d0-447a-88af-44da17e8ced0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_aa3d3ca0-a524-4490-b1d0-8dca81cde314" xlink:to="loc_us-gaap_StockholdersEquity_3d33f2bb-b2d0-447a-88af-44da17e8ced0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d6b3fa06-4354-44ce-bc3b-130362dade6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_aa3d3ca0-a524-4490-b1d0-8dca81cde314" xlink:to="loc_us-gaap_Liabilities_d6b3fa06-4354-44ce-bc3b-130362dade6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_3bfcfe35-2b98-4312-94d6-d2b4a846399b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_aa3d3ca0-a524-4490-b1d0-8dca81cde314" xlink:to="loc_us-gaap_CommitmentsAndContingencies_3bfcfe35-2b98-4312-94d6-d2b4a846399b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_252f9753-597a-4270-a3ab-f5cf2824c61b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_63cf4743-c99f-4af2-b431-667647d511e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_252f9753-597a-4270-a3ab-f5cf2824c61b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_63cf4743-c99f-4af2-b431-667647d511e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7dd2ae32-a26a-47cd-880a-3c450b62e5d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_252f9753-597a-4270-a3ab-f5cf2824c61b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7dd2ae32-a26a-47cd-880a-3c450b62e5d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivableCurrent_f4d1b8bb-0657-4cb1-b9f0-9b42a46283b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrantsReceivableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_252f9753-597a-4270-a3ab-f5cf2824c61b" xlink:to="loc_us-gaap_GrantsReceivableCurrent_f4d1b8bb-0657-4cb1-b9f0-9b42a46283b4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="flks-20230630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f21f8bc2-1c7a-43cc-ba1e-4e8cbbb19621" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_0b3204b4-9a04-4498-b242-b1d5e854b8b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f21f8bc2-1c7a-43cc-ba1e-4e8cbbb19621" xlink:to="loc_us-gaap_OperatingExpenses_0b3204b4-9a04-4498-b242-b1d5e854b8b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_8ff7a779-db2b-4c25-be4d-c8ff27b41cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_c7cddee4-6dad-46ee-8ca6-ed926ae50844" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8ff7a779-db2b-4c25-be4d-c8ff27b41cc8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_c7cddee4-6dad-46ee-8ca6-ed926ae50844" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_a30659c1-b045-4461-80c4-1dd0c15f97c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8ff7a779-db2b-4c25-be4d-c8ff27b41cc8" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_a30659c1-b045-4461-80c4-1dd0c15f97c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_f970dcd9-95fc-4333-adbc-fd633dc5d0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_51e2cd62-2f16-455b-b356-cf0069a3291e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_f970dcd9-95fc-4333-adbc-fd633dc5d0f2" xlink:to="loc_us-gaap_OperatingIncomeLoss_51e2cd62-2f16-455b-b356-cf0069a3291e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_12d2bfb2-11cd-4e82-9b6e-9c7d8c49e180" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_f970dcd9-95fc-4333-adbc-fd633dc5d0f2" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_12d2bfb2-11cd-4e82-9b6e-9c7d8c49e180" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7c2a927b-6cf3-4fd1-bfe6-67969af89e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_2bd8f5e2-9b0f-4c1f-8896-e05083183be7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7c2a927b-6cf3-4fd1-bfe6-67969af89e9c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_2bd8f5e2-9b0f-4c1f-8896-e05083183be7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="flks-20230630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cca06078-70f3-48e5-85d4-5c83271e1f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca10f35e-d0d0-4cab-8ac2-b5af20b64f70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cca06078-70f3-48e5-85d4-5c83271e1f0c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca10f35e-d0d0-4cab-8ac2-b5af20b64f70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_be4d6710-e6e3-4073-bb77-18db6396a457" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cca06078-70f3-48e5-85d4-5c83271e1f0c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_be4d6710-e6e3-4073-bb77-18db6396a457" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f7e55d79-ea65-4c4e-9cb1-1291ed909f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cca06078-70f3-48e5-85d4-5c83271e1f0c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f7e55d79-ea65-4c4e-9cb1-1291ed909f5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d2e1ed3-de19-45a6-98bf-95c285d7856e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_b5c41bae-5134-4387-ae55-1881875fde9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d2e1ed3-de19-45a6-98bf-95c285d7856e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_b5c41bae-5134-4387-ae55-1881875fde9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_InProcessResearchAndDevelopmentTechnology_b0a0ba86-0270-4713-980a-3ab8512cec79" xlink:href="flks-20230630.xsd#flks_InProcessResearchAndDevelopmentTechnology"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d2e1ed3-de19-45a6-98bf-95c285d7856e" xlink:to="loc_flks_InProcessResearchAndDevelopmentTechnology_b0a0ba86-0270-4713-980a-3ab8512cec79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ea3c20aa-1664-45d3-bdb0-db62d9203475" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d2e1ed3-de19-45a6-98bf-95c285d7856e" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ea3c20aa-1664-45d3-bdb0-db62d9203475" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4653af40-1f49-415c-a854-38ba49b525da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d2e1ed3-de19-45a6-98bf-95c285d7856e" xlink:to="loc_us-gaap_NetIncomeLoss_4653af40-1f49-415c-a854-38ba49b525da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_2c679e55-4ef9-4961-a6b2-fc78205bcfeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d2e1ed3-de19-45a6-98bf-95c285d7856e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_2c679e55-4ef9-4961-a6b2-fc78205bcfeb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_87226e87-92ff-4434-8b0c-eef8904e3dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d2e1ed3-de19-45a6-98bf-95c285d7856e" xlink:to="loc_us-gaap_ShareBasedCompensation_87226e87-92ff-4434-8b0c-eef8904e3dc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4fe4a8c6-a3de-4c28-8346-8dbaa78a6ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d2e1ed3-de19-45a6-98bf-95c285d7856e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4fe4a8c6-a3de-4c28-8346-8dbaa78a6ce3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_85756f03-83f8-4241-876a-9bebcadb3c69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d2e1ed3-de19-45a6-98bf-95c285d7856e" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_85756f03-83f8-4241-876a-9bebcadb3c69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0fa798a1-fff4-4f3f-ad39-d139d643836f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_cd0fe84d-4e35-4133-907f-57d88f985b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0fa798a1-fff4-4f3f-ad39-d139d643836f" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_cd0fe84d-4e35-4133-907f-57d88f985b6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_845d3ffe-827a-45be-9bad-1339fd357800" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromOtherEquity_0102a181-8218-4e5d-b648-e7ada03240a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_845d3ffe-827a-45be-9bad-1339fd357800" xlink:to="loc_us-gaap_ProceedsFromOtherEquity_0102a181-8218-4e5d-b648-e7ada03240a6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="flks-20230630.xsd#PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.flex-pharma.com/role/PREPAIDEXPENSESANDOTHERCURRENTASSETSScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9263648e-115f-4fa5-b624-cca13687729c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_7630fb6d-2639-4cc8-9fe0-79432afcd86c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9263648e-115f-4fa5-b624-cca13687729c" xlink:to="loc_us-gaap_OtherAssetsCurrent_7630fb6d-2639-4cc8-9fe0-79432afcd86c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_flks_PrepaidClinicalTrialExpense_0f960767-5e32-4fb5-ad2b-c646ca0d0493" xlink:href="flks-20230630.xsd#flks_PrepaidClinicalTrialExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9263648e-115f-4fa5-b624-cca13687729c" xlink:to="loc_flks_PrepaidClinicalTrialExpense_0f960767-5e32-4fb5-ad2b-c646ca0d0493" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_63c8c433-9aa0-404c-b807-46dcf7ffbd94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9263648e-115f-4fa5-b624-cca13687729c" xlink:to="loc_us-gaap_PrepaidInsurance_63c8c433-9aa0-404c-b807-46dcf7ffbd94" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
